Neurons of the central nervous system in genera I do not multiply after bir
th. Therefore, no replacement or biological renewal of individual cells aff
ected by aging or death is possible. Morphological changes occurring in the
aging brain a re found substantially more pronounced in neurodegenerative
diseases. Systemic degenerations of selective brain areas in these disorder
s, e.g. in Alzheimer's, Parkinson's, Huntington's disease or in amyotrohpic
lateral sclerosis, may be considered as models of accelerated aging and ma
y allow to study the genetic and environmental influences of selective agin
g and cell death in modules of the central nervous system. Although neurode
generative diseases are disparate disorders on the basis of their symptomat
ology and the anatomic distribution of pathologic lesions, they actually sh
are key attributes with respect to biochemical and cellular determinants of
selective vulnerability. Most strikingly, many show a conversion of diseas
e specific acid only recently identified proteins into unsoluble aggregates
which form intra- or extracellular deposits. These protein aggregates may,
over time, affect neuronal function, eventually leading to neurodegenerati
on and neurodegenerative pathology. The pathological process is counterbala
nced by protective mechanisms that may loose their efficacy during normal a
ging. This could explain the late onset of even the inherited neurodegenera
tive disorders. Since the expression of disease-specific proteins is often
not restricted to the affected brain areas (as exemplified by the expressio
n of polyglutamine containing proteins in trinucleotide repeat disorders in
non-affected brain areas and even outside the brain),the anatomical specif
icity of the degenerative process may be determined by associated binding p
roteins. Therapeutic strategies include the reinforcement of physiological
defense mechanisms and intervention at early phases of the pathological bio
chemistry of disease specific proteins.